このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Tien Liang BioTech マネジメント

マネジメント基準チェック /04

現在、CEO に関する十分な情報がありません。

主要情報

Min-Chung Chi

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	no data
CEOの所有権	n/a
経営陣の平均在職期間	データなし
取締役会の平均在任期間	データなし

経営陣の近況

Recent updates

Is Tien Liang BioTech (GTSM:4127) Using Too Much Debt?

Apr 19

Tien Liang BioTech (GTSM:4127) Is Carrying A Fair Bit Of Debt

Jan 04

CEO（最高経営責任者

Min-Chung Chi

no data

在職期間

Min-Chung Chi serves as the President of Tien Liang Biotech Co Ltd.

Tien Liang BioTech マネジメント

マネジメント基準チェック /04

主要情報

経営陣の近況

Tien Liang BioTech Co., Ltd., Annual General Meeting, Jun 28, 2024

Recent updates

First quarter 2024 earnings released: EPS: NT$0.17 (vs NT$0.14 in 1Q 2023)

Investor sentiment deteriorates as stock falls 17%

Full year 2023 earnings released: EPS: NT$39.00 (vs NT$1.30 in FY 2022)

New minor risk - Share price stability

Investor sentiment improves as stock rises 22%

Tien Liang BioTech Co., Ltd., Annual General Meeting, Jun 28, 2024

Third quarter 2023 earnings released: NT$0.03 loss per share (vs NT$0.20 profit in 3Q 2022)

Second quarter 2023 earnings released: EPS: NT$0.12 (vs NT$0.22 in 2Q 2022)

Third quarter 2022 earnings released: EPS: NT$0.20 (vs NT$0.45 in 3Q 2021)

Third quarter 2022 earnings released: EPS: NT$0.20 (vs NT$0.45 in 3Q 2021)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Full year 2021 earnings released: EPS: NT$1.02 (vs NT$1.13 loss in FY 2020)

Second quarter 2021 earnings released: EPS NT$0.26 (vs NT$0.39 loss in 2Q 2020)

First quarter 2021 earnings released: NT$0.26 loss per share (vs NT$0.045 loss in 1Q 2020)

Is Tien Liang BioTech (GTSM:4127) Using Too Much Debt?

Full year 2020 earnings released: NT$1.13 loss per share (vs NT$1.02 loss in FY 2019)

New 90-day low: NT$10.55

Tien Liang BioTech (GTSM:4127) Is Carrying A Fair Bit Of Debt

Third quarter 2020 earnings released: NT$0.40 loss per share

New 90-day low: NT$10.60

New 90-day low: NT$10.80

New 90-day low - NT$11.45

First half earnings released

CEO（最高経営責任者

在職期間

Tien Liang BioTech マネジメント

マネジメント 基準チェック /04

主要情報

経営陣の近況

Tien Liang BioTech Co., Ltd., Annual General Meeting, Jun 28, 2024

Recent updates

First quarter 2024 earnings released: EPS: NT$0.17 (vs NT$0.14 in 1Q 2023)

Investor sentiment deteriorates as stock falls 17%

Full year 2023 earnings released: EPS: NT$39.00 (vs NT$1.30 in FY 2022)

New minor risk - Share price stability

Investor sentiment improves as stock rises 22%

Tien Liang BioTech Co., Ltd., Annual General Meeting, Jun 28, 2024

Third quarter 2023 earnings released: NT$0.03 loss per share (vs NT$0.20 profit in 3Q 2022)

Second quarter 2023 earnings released: EPS: NT$0.12 (vs NT$0.22 in 2Q 2022)

Third quarter 2022 earnings released: EPS: NT$0.20 (vs NT$0.45 in 3Q 2021)

Third quarter 2022 earnings released: EPS: NT$0.20 (vs NT$0.45 in 3Q 2021)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Full year 2021 earnings released: EPS: NT$1.02 (vs NT$1.13 loss in FY 2020)

Second quarter 2021 earnings released: EPS NT$0.26 (vs NT$0.39 loss in 2Q 2020)

First quarter 2021 earnings released: NT$0.26 loss per share (vs NT$0.045 loss in 1Q 2020)

Is Tien Liang BioTech (GTSM:4127) Using Too Much Debt?

Full year 2020 earnings released: NT$1.13 loss per share (vs NT$1.02 loss in FY 2019)

New 90-day low: NT$10.55

Tien Liang BioTech (GTSM:4127) Is Carrying A Fair Bit Of Debt

Third quarter 2020 earnings released: NT$0.40 loss per share

New 90-day low: NT$10.60

New 90-day low: NT$10.80

New 90-day low - NT$11.45

First half earnings released

CEO（最高経営責任者

在職期間

マネジメント基準チェック /04